Seasonal Allergic Rhinitis
Conditions
Keywords
Imatinib, allergic inflammation, out of allergy season, repeated nasal allergen, seasonal allergic rhinitis, sensitive, Timothy grass pollen, c-kit inhibition
Brief summary
This study will assess the effects of Imatinib on allergic inflammation following repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timothy grass pollen.
Interventions
DRUGImatinib
Sponsors
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Healthy male non-smoking subjects aged 18-55 years, with a history of seasonal allergic rhinitis consistent with Timothy grass pollen allergy. They must show: a positive skin prick test to Timothy grass pollen (wheal difference Timothy grass pollen - negative control ≥ 3 mm) at or within the 12 months preceding the screening visit and demonstrate symptomatic worsening (TNSS ≥4) within one hour after nasal allergen challenge * Be otherwise healthy with no health problems that may jeopardize the subjects participating in the study, absence of history of other significant allergies. * Subjects and their partners must agree to use effective contraceptive measures from screening until the end of study visit.
Exclusion criteria
* Respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function. * Structural nasal abnormalities or nasal polyps on examination, a history of frequent nose bleeding, recent nasal surgery or recent (within 8 weeks prior to baseline visit) or recent (four weeks) or ongoing upper or lower respiratory tract infection. * Use of any medication that would affect the response to the allergen challenge (e.g. corticosteroids, decongestants, anti-histamines, medications with anti-inflammatory effects) or any other nasally applied medication within 14 days prior to allergen challenge (30 days for systemic anti-inflammatory therapy including oral corticosteroids), or known to influence Imatinib bioavailability or clearance * History or laboratory evidence of acute or chronic renal insufficiency or abnormal liver function. * Subjects may voluntarily withdraw from or be withdrawn from the study at the discretion of the investigator or the sponsor at any time. Subjects may be withdrawn from the study prematurely for one of the following reasons: * Subject withdrew consent * Upper respiratory tract infection * Presence of allergic rhinitis symptoms in the screening period or prior to pre-wash on Day 1 * A past medical history of inherited heart disease, valve defect, cardiomyopathy, rheumatic fever, arrhythmias, cardiac interventions or clinically significant ECG abnormalities. * Adverse events and non-tolerable symptoms resulting from allergen challenge * Administration of a concomitant medication (other than those randomized to receive Fluticasone propionate) that would impact on the study results (e.g. corticosteroids), including any subjects requiring asthma therapy (inhaled or systemic). Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effect of Imatinib on the reduction of mast cell degranulation (measured by β-tryptase and PGD2) in response to allergen challenge | — |
Secondary
| Measure | Time frame |
|---|---|
| Additional markers of inflammation following nasal allergen challenge (NAC): | — |
| Enumeration of eosinophils in nasal lavage following NAC | — |
| Total nasal symptom score (TNSS) following NAC | — |
| Soluble mediators collected from adsorption onto nasal filter papers following NAC, with a focus on Th2-associated cytokines | — |
Countries
United Kingdom
Outcome results
None listed